Targeting a specific protein to treat lung adenocarcinoma
Official title: Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
Funded at University of Tx Md Anderson Can Ctr · NIH-11085121 · Data updated 2026-11-12
This study is looking at how a protein called NSD2 affects lung adenocarcinoma, the most common type of lung cancer, to help create a new treatment that could work better for patients by targeting this protein.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $652,695 |
| NIH project number | 5R01CA272844-03 |
| Project ID | NIH-11085121 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have not responded adequately to existing treatments.
✕Less likely to help
Patients with other types of lung cancer or those who are not diagnosed with lung adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on understanding how the protein NSD2 contributes to the progression of lung adenocarcinoma, the most common type of lung cancer. By investigating the mechanisms through which NSD2 operates, the researchers aim to develop a new therapy that targets this protein, potentially improving treatment outcomes for patients. The study will utilize advanced pre-clinical models to test the effectiveness of a novel NSD2 inhibitor, which could lead to a more effective treatment strategy that combines multiple therapeutic approaches. Patients may benefit from a more tailored and effective treatment plan that addresses the complexities of their cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for lung adenocarcinoma, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting similar epigenetic factors in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Mazur, Pawel K. — University of Tx Md Anderson Can Ctr
- Study coordinator: Mazur, Pawel K.
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.